Login to Your Account



CAT Slowing Down Trabio Following Failed Phase II/III

By Nuala Moran


Wednesday, November 17, 2004
LONDON - Cambridge Antibody Technology Group plc has begun to wind down expenditure on Trabio, the first antibody it has developed in-house, after the product failed to meet its primary endpoint in a European Phase II/III pivotal trial. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription